2019 Clinical Practice Guidelines for Type 2 Diabetes Mellitus in Korea

Mee Kyoung Kim; Seung Hyun Ko; Bo Yeon Kim; Eun Seok Kang; Junghyun Noh; Soo Kyung Kim; Seok O Park; Kyu Yeon Hur; Suk Chon; Min Kyong Moon; Nan Hee Kim; Sang Yong Kim; Sang Youl Rhee; Kang Woo Lee; Jae Hyeon Kim; Eun Jung Rhee; SungWan Chun; Sung Hoon Yu; Dae Jung Kim; Hyuk Sang Kwon; Kyong Soo Park; Committee of Clinical Practice Guidelines, Korean Diabetes Association

doi:10.4093/dmj.2019.0137

2019 Clinical Practice Guidelines for Type 2 Diabetes Mellitus in Korea

Diabetes Metab J. 2019 Aug;43(4):398-406. doi: 10.4093/dmj.2019.0137.

Authors

Mee Kyoung Kim¹, Seung Hyun Ko², Bo Yeon Kim³, Eun Seok Kang⁴, Junghyun Noh⁵, Soo Kyung Kim⁶, Seok O Park⁷, Kyu Yeon Hur⁸, Suk Chon⁹, Min Kyong Moon¹⁰, Nan Hee Kim¹¹, Sang Yong Kim¹², Sang Youl Rhee⁹, Kang Woo Lee¹³, Jae Hyeon Kim⁸, Eun Jung Rhee¹⁴, SungWan Chun¹⁵, Sung Hoon Yu¹⁶, Dae Jung Kim¹⁷, Hyuk Sang Kwon¹⁸, Kyong Soo Park^{19

20}; Committee of Clinical Practice Guidelines, Korean Diabetes Association

Affiliations

¹ Division of Endocrinology and Metabolism, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
² Division of Endocrinology and Metabolism, Department of Internal Medicine, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Suwon, Korea.
³ Division of Endocrinology and Metabolism, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, Bucheon, Korea.
⁴ Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
⁵ Division of Endocrinology and Metabolism, Department of Internal Medicine, Inje University Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Korea.
⁶ Division of Endocrinology and Metabolism, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Korea.
⁷ Gwangmyeong Sungae Hospital, Gwangmyeong, Korea.
⁸ Division of Endocrinology and Metabolism, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
⁹ Department of Endocrinology and Metabolism, Kyung Hee University School of Medicine, Seoul, Korea.
¹⁰ Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea.
¹¹ Department of Internal Medicine, Korea University College of Medicine, Ansan, Korea.
¹² Division of Endocrinology and Metabolism, Department of Internal Medicine, Chosun University College of Medicine, Gwangju, Korea.
¹³ Sejong St. Mary's Diabetes and Endocrine Clinic, Sejong, Korea.
¹⁴ Division of Endocrinology and Metabolism, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.
¹⁵ Department of Internal Medicine, Soonchunhyang University Cheonan Hospital, Soonchunhyang University College of Medicine, Cheonan, Korea.
¹⁶ Department of Endocrinology and Metabolism, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, Korea.
¹⁷ Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, Korea.
¹⁸ Division of Endocrinology and Metabolism, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea. drkwon@catholic.ac.kr.
¹⁹ Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Korea.
²⁰ Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.

Abstract

The Committee of Clinical Practice Guidelines of the Korean Diabetes Association revised and updated the 6th Clinical Practice Guidelines in 2019. Targets of glycemic, blood pressure, and lipid control in type 2 diabetes mellitus (T2DM) were updated. The obese and overweight population is increasing steadily in Korea, and half of the Koreans with diabetes are obese. Evidence-based recommendations for weight-loss therapy for obesity management as treatment for hyperglycemia in T2DM were provided. In addition, evidence from large clinical studies assessing cardiovascular outcomes following the use of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide 1 receptor agonists in patients with T2DM were incorporated into the recommendations.

Keywords: Diabetes mellitus, type 2; Diagnosis; Practice guideline; Therapeutics.

Publication types

Practice Guideline
Review

MeSH terms

Adult
Antihypertensive Agents / therapeutic use*
Diabetes Mellitus, Type 2 / diagnosis
Diabetes Mellitus, Type 2 / drug therapy*
Diabetes Mellitus, Type 2 / epidemiology*
Diabetic Nephropathies / drug therapy
Glucagon-Like Peptide-1 Receptor / agonists*
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
Hypoglycemic Agents / therapeutic use*
Obesity / drug therapy
Prevalence
Republic of Korea / epidemiology
Sodium-Glucose Transporter 2 Inhibitors / therapeutic use*
Weight Loss

Substances

Antihypertensive Agents
GLP1R protein, human
Glucagon-Like Peptide-1 Receptor
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hypoglycemic Agents
Sodium-Glucose Transporter 2 Inhibitors